Adamson A S, Francis J L, Witherow R O, Snell M E
Department of Urology, St Mary's Hospital, London, UK.
Br J Urol. 1994 Aug;74(2):204-9. doi: 10.1111/j.1464-410x.1994.tb16587.x.
To determine the factor-X activating procoagulant activity (FXAA) of prostatic tissue removed at transurethral resection in a specific chromogenic assay.
FXAA was extracted from transurethrally resected prostatic tissue using a cryofragmentation technique. Tissue from 50 patients with prostate cancer was analysed and compared with that from 36 control patients with benign prostatic-hypertrophy. Enzyme activities were assayed in a two stage chromogenic assay and correlated with conventional markers of tumour aggressiveness.
FXAA was found to be significantly lower (P < 0.001) in tissue from malignant prostates compared with benign prostatic hypertrophy tissue. Loss of FXAA was also related to Gleason grade (P < 0.03), percentage of chips involved by tumour (P < 0.04) and bone scan status (P < 0.02). Using antibody inhibition tests this procoagulant was characterized as being a factor VII/tissue factor complex.
Malignant change in the prostate is associated with a reduction in FXAA and this may be an important factor in prostatic tumour growth and dissemination.
采用特定的显色测定法，测定经尿道前列腺切除术中切除的前列腺组织的凝血因子X激活促凝活性（FXAA）。
采用冷冻破碎技术从经尿道切除的前列腺组织中提取FXAA。对50例前列腺癌患者的组织进行分析，并与36例良性前列腺增生对照患者的组织进行比较。酶活性通过两阶段显色测定法进行检测，并与肿瘤侵袭性的传统标志物相关联。
与良性前列腺增生组织相比，恶性前列腺组织中的FXAA显著降低（P < 0.001）。FXAA的降低还与Gleason分级（P < 0.03）、肿瘤累及的组织块百分比（P < 0.04）和骨扫描状态（P < 0.02）有关。通过抗体抑制试验，该促凝剂被鉴定为凝血因子VII/组织因子复合物。
前列腺的恶性变化与FXAA降低有关，这可能是前列腺肿瘤生长和扩散的一个重要因素。
